{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/10/3309444/0/fr/Communiqu%C3%A9-de-presse-Sanofi-fait-le-point-sur-l-%C3%A9tude-de-phase-3-MOBILIZE-qui-%C3%A9value-le-riliprubart-dans-la-polyneuropathie-inflammatoire-d%C3%A9my%C3%A9linisante-chronique.html", "message": "News view counter 790536 successfully enlarged"}